Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Voyager Therapeut (VYGR)

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 228,429
  • Shares Outstanding, K 38,456
  • Annual Sales, $ 37,420 K
  • Annual Income, $ -71,200 K
  • 60-Month Beta 1.10
  • Price/Sales 5.92
  • Price/Cash Flow N/A
  • Price/Book 2.92
Trade VYGR with:

Options Overview Details

View History
  • Implied Volatility 106.05% ( -12.60%)
  • Historical Volatility 93.44%
  • IV Percentile 15%
  • IV Rank 14.14%
  • IV High 412.88% on 10/04/21
  • IV Low 55.52% on 07/21/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 335
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 10,575
  • Open Int (30-Day) 8,000

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.56
  • Number of Estimates 3
  • High Estimate -0.52
  • Low Estimate -0.59
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.61 +24.08%
on 06/16/22
6.54 -12.54%
on 06/03/22
-0.33 (-5.45%)
since 05/27/22
3-Month
4.61 +24.08%
on 06/16/22
10.60 -46.04%
on 04/20/22
-2.75 (-32.47%)
since 03/28/22
52-Week
2.46 +132.52%
on 10/05/21
10.60 -46.04%
on 04/20/22
+1.35 (+30.89%)
since 06/28/21

Most Recent Stories

More News
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs

VCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9...

VYGR : 5.72 (-3.70%)
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting

Single dose of TRACER AAV vector encoding anti-HER2 antibody reduced CNS tumor burden and extended survival across multiple mouse models of breast cancer...

VYGR : 5.72 (-3.70%)
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

VRTX : 276.42 (-3.79%)
CLVS : 1.6700 (-2.34%)
GBT : 29.62 (-0.44%)
VYGR : 5.72 (-3.70%)
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus

FATE reports a narrower loss and higher collaboration revenues in the first quarter.

VRTX : 276.42 (-3.79%)
FATE : 24.71 (-5.87%)
VYGR : 5.72 (-3.70%)
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates

Acadia (ACAD) posts wider-than-expected loss for the first quarter of 2022 while revenues miss estimates.

VRTX : 276.42 (-3.79%)
ACAD : 13.94 (-4.78%)
VYGR : 5.72 (-3.70%)
STOK : 12.55 (-6.55%)
Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.

VRTX : 276.42 (-3.79%)
HZNP : 81.94 (-4.15%)
VYGR : 5.72 (-3.70%)
ALGS : 1.3200 (-2.22%)
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -300% and 97.67%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYGR : 5.72 (-3.70%)
PBYI : 2.80 (-3.11%)
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS...

VYGR : 5.72 (-3.70%)
Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

RHHBY : 41.4500 (-1.82%)
VRTX : 276.42 (-3.79%)
VYGR : 5.72 (-3.70%)
BPMC : 53.63 (-6.54%)
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

VRTX : 276.42 (-3.79%)
VYGR : 5.72 (-3.70%)
EDIT : 12.34 (-5.37%)
ALGS : 1.3200 (-2.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

3rd Resistance Point 6.89
2nd Resistance Point 6.56
1st Resistance Point 6.25
Last Price 5.72
1st Support Level 5.61
2nd Support Level 5.28
3rd Support Level 4.97

See More

52-Week High 10.60
Fibonacci 61.8% 7.49
Fibonacci 50% 6.53
Last Price 5.72
Fibonacci 38.2% 5.57
52-Week Low 2.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar